A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)

Daiichi Sankyo, Inc.0 个研究点目标入组 290 人开始时间: 2016年8月9日最近更新: 2024年8月5日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Daiichi Sankyo, Inc.
入组人数: 290

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Subjects must satisfy all of the following criteria to be included in the study:
•1. Male or female pediatric subjects between birth (defined as 38 weeks gestational age) and less than 18 years of age at the time of consent.
•2. Pediatric subjects with the presence of documented VTE confirmed by appropriate diagnostic imaging and requiring anticoagulant therapy for at least 90 days.
•-Subjects <6 months old (Cohort 5) with the presence of documented VTE confirmed by appropriate diagnostic imaging and requiring anticoagulant therapy for at least 6 to12 weeks
•3. Subjects must have received at least 5 days of heparin (LMWH or SP Xa inhibitors or UFH according to the edoxaban label for VTE treatment) therapy prior to randomization to treat the newly identified index VTE. In addition, prior to being randomized to edoxaban or SOC, subjects initially treated with VKA are
•recommended to have an INR < 2.0.
•4. Subject and/or parent(s)/legal guardian(s) or legally acceptable representative is informed and provides signed consent for the child to participate in the study with edoxaban treatment. Pediatric subjects with appropriate intellectual maturity will be required to sign an assent form in addition to the signed informed consent from the parent(s)/legal guardian(s) or any legally acceptable representative.
•5. Female subjects who have menarche must test negative for pregnancy at Screening and must consent to avoid becoming pregnant by using an approved contraception method throughout the study.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 274
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Subjects who meet any of the following criteria will be disqualified from entering the
•1. Subjects with active bleeding or high risk of bleeding contraindicating treatment with LMWH, SP Xa inhibitors, VKAs, or direct oral anticoagulants (DOACs; identified high risk of bleeding during prior experimental administration of DOACs).
•2. Subjects who have been or are being treated with thrombolytic agents, thrombectomy or insertion of a caval filter for the newly identified index VTE.
•3. Administration of antiplatelet therapy is contraindicated in both arms except for low dose aspirin defined as 1-5 mg/Kg/day with maximum of 100 mg/day.
•4. Administration of rifampin is prohibited during the study and subjects on concomitant use of rifampin are excluded.
•5. Subjects with hepatic disease associated with coagulopathy leading to a clinically relevant bleeding risk (aPTT> 50 seconds or international normalized ratio [INR] > 2.0 not related to anticoagulation therapy) or ALT >5 x the upper limit of normal (ULN) or total bilirubin > 2x ULN with direct bilirubin > 20% of the total at Screening Visit.
•6. Subjects with glomerular filtration rate (GFR) < 30% of normal for age and size.
•7. Subjects with stage 2 hypertension defined as blood pressure (BP) systolic and/or diastolic confirmed > 99th percentile + 5 mmHg.
•8. Subject with thrombocytopenia < 50 × 109/L at Screening Visit. Subjects with a history of heparin-induced thrombocytopenia may be enrolled in the study at the Investigator’s discretion.
•9. Life expectancy less than the expected study treatment duration (3 months).
•10. Subjects who are known to be pregnant or breastfeeding.
•11. Subjects with any condition that, as judged by the Investigator, would place the subject at increased risk of harm if he/she participated in the study ncluding contraindicated medications identified in Appendix 17.4.
•12. Subjects who participated in another clinical study or were treated with an experimental therapy with less than 30-day washout period prior to identifying the qualifying index VTE.

研究者

发起方

Daiichi Sankyo, Inc.

相似试验

进行中（未招募）

1 期

EUCTR2016-000991-49-NODaiichi Sankyo, Inc.274

进行中（未招募）

1 期

A Phase 3, Open-Label, Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban and to compare the safety and efficacy of Edoxaban with standard of care treatment in Paediatric Patients confirmed as requiring treatment for a blood clotMedDRA version: 19.0Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866venous thromboembolism

EUCTR2016-000991-49-ESDaiichi Sankyo, Inc.274

进行中（未招募）

1 期

A Phase 3, Open-Label, Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban and to compare the safety and efficacy of Edoxaban with standard of care treatment in Paediatric Patients confirmed as requiring treatment for a blood clotMedDRA version: 21.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866venous thromboembolism

EUCTR2016-000991-49-NLDaiichi Sankyo, Inc.274

进行中（未招募）

1 期

A Phase 3, Open-Label, Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban and to compare the safety and efficacy of Edoxaban with standard of care treatment in Paediatric Patients confirmed as requiring treatment for a blood clotMedDRA version: 21.1Level: LLTClassification code 10066899Term: Venous thromboembolismSystem Organ Class: 100000004866venous thromboembolism

EUCTR2016-000991-49-PLDaiichi Sankyo, Inc.290

进行中（未招募）

1 期

EUCTR2016-000991-49-CZDaiichi Sankyo, Inc.274